Butyrfentanyl: Difference between revisions
m WP:CHECKWIKI error fix for #61. Punctuation goes before References. Do general fixes if a problem exists. - using AWB (9399) |
No edit summary |
||
| Line 24: | Line 24: | ||
'''Butyr-fentanyl''', often abbreviated as '''B-F''', or '''Butyrylfentanyl''' (not to be confused with [[3-methylfentanyl]]) is a potent short-acting synthetic [[opioid]] [[analgesic]] [[medication|drug]]. It is an analogue of [[fentanyl]] with around 1/4 the potency of fentanyl. One of first signs of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned under the position 10486 as N-butyramide fentanyl analog.<ref name="The College on Problem of Drug Dependence">[http://www.cpdd.vcu.edu/DEC_ARCHIVES/DEC/acrobat/DECindices.pdf The College on Problem of Drug Dependence], Foreword to the Drug Evaluation Committee (DEC) Analgesic, Stimulant, and Depressant Drug Indices</ref> This document also states that the article describing its clinical effects (analgesic studies, m-, d-, k-Opioid receptor binding and in vitro measures of drug efficacy, antinociceptive and narcotic properties) was published in 1987. It is an agonist at [[mu opioid receptor]]s.<ref name="Part II">[http://content.lib.utah.edu/utils/getfile/collection/etd1/id/1285/filename/1341.pdf Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine] Mario Enrique Alburges</ref> |
'''Butyr-fentanyl''', often abbreviated as '''B-F''', or '''Butyrylfentanyl''' (not to be confused with [[3-methylfentanyl]]) is a potent short-acting synthetic [[opioid]] [[analgesic]] [[medication|drug]]. It is an analogue of [[fentanyl]] with around 1/4 the potency of fentanyl. One of first signs of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned under the position 10486 as N-butyramide fentanyl analog.<ref name="The College on Problem of Drug Dependence">[http://www.cpdd.vcu.edu/DEC_ARCHIVES/DEC/acrobat/DECindices.pdf The College on Problem of Drug Dependence], Foreword to the Drug Evaluation Committee (DEC) Analgesic, Stimulant, and Depressant Drug Indices</ref> This document also states that the article describing its clinical effects (analgesic studies, m-, d-, k-Opioid receptor binding and in vitro measures of drug efficacy, antinociceptive and narcotic properties) was published in 1987. It is an agonist at [[mu opioid receptor]]s.<ref name="Part II">[http://content.lib.utah.edu/utils/getfile/collection/etd1/id/1285/filename/1341.pdf Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine] Mario Enrique Alburges</ref> |
||
Butyrfentanyl has no legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug. This compound is not currently scheduled in the USA, but most likely falls under the purview of the federal and many state analogue drug laws. Butyrfentanyl is illegal in the United Kingdom owing to its chemical similarity to fentanyl. |
|||
Butyrfentanyl is called first opioid [[research chemical]] (RC, called also [[designer drug]]). It has no clinical applications yet, but according to various drug users' forums, it is used recreationaly.<ref name="Drugs-forum.com">[http://www.drugs-forum.com/forum/showthread.php?t=183677 Drugs-forum.com], contains descriptions of experiences with Butyr-fentanyl</ref> Its effects include: anaesthesia and analgesia, but weaker than in case of [[fentanyl]]; euphoria, greater than in case of [[fentanyl]]. Butyrfentanyl doesn't cause that great risk of [[respiratory depression]], as fentanyl does,<ref name="Part II" /> and it is not scheduled. All these properties made it an attractive research chemical. |
|||
==Pharmacokinetics== |
==Pharmacokinetics== |
||
| Line 46: | Line 46: | ||
* {{cite journal | author = Brine GA, Boldt KG, Huang P-T, Sawyer DK, Carroll FI | title = Carbon-13 nuclear magnetic resonance spectra of fentanyl analogs | year = 2009 | doi = 10.1002/jhet.5570260329 | journal = Journal of Heterocyclic Chemistry | volume = 26 | issue = 3 | pages = 677 }} |
* {{cite journal | author = Brine GA, Boldt KG, Huang P-T, Sawyer DK, Carroll FI | title = Carbon-13 nuclear magnetic resonance spectra of fentanyl analogs | year = 2009 | doi = 10.1002/jhet.5570260329 | journal = Journal of Heterocyclic Chemistry | volume = 26 | issue = 3 | pages = 677 }} |
||
{{refend}} |
{{refend}} |
||
== External links == |
|||
* [http://researchchemicalreview.com/tag/buy-butyr-fentanyl/ Research Chemicals Reviews] |
|||
* [http://www.drugs-forum.com/forum/showthread.php?t=183677 Drugs-forum.com] |
|||
{{Analgesics}} |
{{Analgesics}} |
||
Revision as of 03:50, 23 August 2013
| File:Butyrfentanyl.jpg | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30N2O |
| Molar mass | 350.5 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Butyr-fentanyl, often abbreviated as B-F, or Butyrylfentanyl (not to be confused with 3-methylfentanyl) is a potent short-acting synthetic opioid analgesic drug. It is an analogue of fentanyl with around 1/4 the potency of fentanyl. One of first signs of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned under the position 10486 as N-butyramide fentanyl analog.[1] This document also states that the article describing its clinical effects (analgesic studies, m-, d-, k-Opioid receptor binding and in vitro measures of drug efficacy, antinociceptive and narcotic properties) was published in 1987. It is an agonist at mu opioid receptors.[2]
Butyrfentanyl has no legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug. This compound is not currently scheduled in the USA, but most likely falls under the purview of the federal and many state analogue drug laws. Butyrfentanyl is illegal in the United Kingdom owing to its chemical similarity to fentanyl.
Pharmacokinetics
Butyrfentanyl binds to the opioid receptor. During the studies of in vitro inhibition of specific [3H] fentanyl binding to the opioid receptor, the order of analogues was: (±)-cis-3-methylfentanyl > fentanyl = alpha-methylfentanyl > butyrylfentanyl > benzylfentanyl.[2] The studies in inhibition studies on binding affinity achieved the same order of analogues. It means that butyrfentantyl is a less potent opioid-agonist than fentanyl. On the other side, during in vitro studies of cross-reactivity with the fentanyl antibody between fentanyl and the fentanyl analogs examined, revealed order: fentanyl = butyrylfentanyl > (±)-cis-3-methylfentanyl > benzylfentanyl > alpha-methylfentanyl.[2] High cross-reactivity may be the effect of the shape of the molecule - the shape of butyrfentanyl is closest to the original fentanyl molecule, which makes it easy to bind by fentanyl antibodies.
The opioid receptor affinity of fentanyl and its analogs was determined from their inhibitory potency in a binding assay with [3H] fentanyl as the radioligand. The Ki value for butyrfentanyl was Ki=32 ± 4.1 nM. Comparing to fentanyl's Ki (Ki=1.06 ± 0.15 nM), butyrfentanyl's ability to displace [3H] fentanyl is low and it requires high concentrations of the drug.[2]
During behavioral studies there was no evidence of causing adverse effects which accompany fentanyl's use. Animals injected with 45μg/kg i.v. showed no behavioral respones in mice: straub tail, truncal and limbs rigidity, respiratory depression. These respones where observed in animals injected with 15 μg/kg fentanyl i.v.[2]
Studies on urinary excretion revealed that almost all of the injected butyrfentanyl was excreted or metabolized within the first 3 h after injection, and only very low concentrations were still detectable after 3 h.[2] Urinary concentrations of butyrylfentanyl from animals injected with 15 μg/kg and 45 μg/kg i.v. were measured by two techniques: radioreceptorassay and gas chromatography/mass spectrometry (GC/MS).
References
- ^ The College on Problem of Drug Dependence, Foreword to the Drug Evaluation Committee (DEC) Analgesic, Stimulant, and Depressant Drug Indices
- ^ a b c d e f Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine Mario Enrique Alburges
Further reading
- Higashikawa Y, Suzuki S (2008). "Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues". Forensic Toxicology. 26 (1): 1–5. doi:10.1007/s11419-007-0039-1.
{{cite journal}}: Unknown parameter|month=ignored (help) - Alburges ME, Hanson GR, Gibb JW, Sakashita CO, Rollins DE (1992). "Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine". J Anal Toxicol. 16 (1): 36–41. PMID 1322477.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Woods J, Medzihradsky F, Smith C, Winger G, Gmerek D (1988). "Evaluation of new compounds for opioid activity: 1987 annual report". NIDA Res. Monogr. 81: 543–90. PMID 3136388.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Aceto M, Bowman E, Harris L, May E (1988). "Dependence studies of new compounds in the rhesus monkey, rat, and mouse, 1987". NIDA Res. Monogr. 81: 485–542. PMID 3136386.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Brine GA, Boldt KG, Huang P-T, Sawyer DK, Carroll FI (2009). "Carbon-13 nuclear magnetic resonance spectra of fentanyl analogs". Journal of Heterocyclic Chemistry. 26 (3): 677. doi:10.1002/jhet.5570260329.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |